我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 bbgi global infrastructure s.a.
相关临床试验
87
12 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
1912
进行中（未招募）
3
3.5%
已完成
43
49.4%
尚未招募
9
10.3%
招募中
终止
6
6.9%
Unknown
13
14.9%
撤回
4
4.6%
暂无批准数据
• Analysis of 50 countries shows significant disparities in biologic medication access for atopic dermatitis, with high-SDI countries having 28.2 times greater utilization rates than lower-middle/middle-SDI nations. • Global biologic use increased dramatically from 2017 to 2022, expanding from just 3 high-SDI countries to 50 countries, with average utilization rising from 1.1 to 192.9 units per 100,000 individuals. • Research reveals sociodemographic status, rather than disease burden, primarily determines biologic access, highlighting financial barriers in lower-income countries despite medical need.
